I-20mg ye-Retatrutide yokuLahla kobunzima be-Peptide Lyophilized Powder Reta Vials Injection 99% Retatrutide

Ingcaciso yeMveliso
I-Retatrutide yinoveli i-peptide ye-agonist ephindwe kathathu ejolise kwi-glucagon receptor (GCGR), i-glucose exhomekeke kwi-insulinotropic polypeptide receptor (GIPR), kunye ne-glucagon-like peptide-1 receptor (GLP-1R). I-Retatrutide ivuselela i-GCGR yabantu, i-GIPR, kunye ne-GLP-1R kunye nemilinganiselo ye-EC50 ye-5.79, 0.0643, kunye ne-0.775 nM, ngokulandelanayo, kunye ne-mouse ye-GCGR, i-GIPR, kunye ne-GLP-1R kunye nemilinganiselo ye-EC50 ye-2.32, 0.0.191, kunye ne-nM1974, kunye ne-nM1979, kunye ne-nM. Isebenza njengesixhobo sophando esibalulekileyo kwisifundo sokutyeba kunye nokuphazamiseka kwemetabolism.

I-Retatrutide isebenze ngokufanelekileyo indlela yokubonisa i-GLP-1R kwaye ivuselele ukukhutshwa kwe-insulin exhomekeke kwi-glucose ngokusebenza kuzo zombini i-GIP kunye ne-GLP-1 receptors. Le peptide yokwenziwa ibonisa iimpawu ezinamandla ze-hypoglycemic kwaye iye yaphuhliswa njenge-anti-diabetic compound ye-Type 2 Diabetes (T2D). Ikhuthaza ukukhutshwa kwe-insulin kwaye icinezela ukukhutshwa kweglucagon ngendlela exhomekeke kwi-glucose.

Ukongezelela, i-Retatrutide ibonakaliswe ukulibazisa ukukhutshwa kwesisu, ukunciphisa kokubili ukuzila kunye namanqanaba e-glucose e-postprandial, ukunciphisa ukutya, kunye nokunciphisa ubunzima bomzimba kubantu abane-T2D.

Umsebenzi webhayoloji
I-Retatrutide (LY3437943) yi-peptide enye ye-lipid-conjugated esebenza njenge-agonist enamandla ye-GCGR yabantu, i-GIPR, kunye ne-GLP-1R. Xa kuthelekiswa neglucagon yabantu bomthonyama kunye ne-GLP-1, i-Retatrutide ibonisa amandla aphantsi kwi-GCGR kunye ne-GLP-1R (0.3 × kunye ne-0.4 ×, ngokulandelanayo) kodwa ibonisa amandla aphuculwe ngokuphawulekayo (8.9 ×) kwi-GIPR xa kuthelekiswa ne-glucose-exhomekeke kwi-insulinotropic polypeptide (GIP).

Indlela yokwenza
Kuphononongo olubandakanya iimpuku zesifo seswekile ezine-nephropathy, ulawulo lwe-Retatrutide lunciphise kakhulu i-albuminuria kunye nokuphuculwa kwezinga lokuhluza i-glomerular. Esi siphumo sokukhusela sibangelwa ukusetyenziswa kwe-GLP-1R / GR-exhomekeke kwindlela yokubonisa uphawu, edibanisa izenzo ezichasayo kunye ne-anti-apoptotic kwizicubu zezintso.

I-Retatrutide iphinda imodareyithe ngokuthe ngqo ukunyibilika kweglomerular, iphucula isakhono sokuxinana komchamo. Ukufunyaniswa kwangaphambili kubonisa ukuba, xa kuthelekiswa nonyango oluqhelekileyo lwesifo sezintso ezifana ne-ACE inhibitors kunye ne-ARBs, i-Retatrutide ivelisa ukuncipha okucacileyo kwi-albuminuria emva kweeveki ezine kuphela zonyango. Ngaphaya koko, ibonise ukusebenza kakuhle kakhulu ekunciphiseni uxinzelelo lwegazi lwe-systolic kune-ACE inhibitors okanye ii-ARBs, kungekho ziphumo zibi zibonwayo.

Imiphumela
Iziphumo eziqhelekileyo ze-Retatrutide ziyi-gastrointestinal yendalo, kuquka isicaphucaphu, isifo sohudo, ukuhlanza, kunye nokuqunjelwa. Ezi mpawu jikelele zinobulali ukuya kumodareyitha kwaye zikholisa ukusombulula ngokuncipha kwethamo. Phantse i-7% yezifundo nazo zichaze ukuvakalelwa kwesikhumba. Ukunyuka kwesantya senhliziyo kwabonwa kwiiveki ze-24 kumaqela aphezulu edosi, eyathi kamva yabuyela kumanqanaba asisiseko.